Cd19tm1(cre)Cgn/Cd19+ Myd88em1.1Rsky/Myd88+
involves: C57BL/6NTac
|
abnormal splenic cell ratio |
J:308792
|
enlarged spleen |
J:308792
|
normal
hematopoietic system phenotype |
J:308792
|
increased germinal center B cell number |
J:308792
|
increased IgM level |
J:308792
|
increased plasma cell number |
J:308792
|
Cd19tm1(cre)Cgn/Cd19+ Myd88em1.1Rsky/Myd88em1.1Rsky
involves: C57BL/6NTac
|
increased B cell proliferation |
J:308792
|
Cd19tm1(cre/ERT2)Rsky/Cd19+ Myd88em1.1Rsky/Myd88+
involves: 129P2/OlaHsd * C57BL/6NTac
|
increased IgM level |
J:308792
|
increased plasma cell number |
J:308792
|
Ighg1tm1(cre)Cgn/Ighg1+ Myd88em1.1Rsky/Myd88+
involves: 129P2/OlaHsd * C57BL/6NTac
|
abnormal somatic hypermutation frequency |
J:308792
|
abnormal splenic cell ratio |
J:308792
|
normal
hematopoietic system phenotype |
J:308792
|
increased germinal center B cell number |
J:308792
|
increased IgM level |
J:308792
|
increased plasma cell number |
J:308792
|
Myd88lkd/Myd88lkd
C57BL/6-Myd88lkd
|
abnormal adaptive immunity |
J:110094
|
abnormal cell-mediated immunity |
J:110094
|
abnormal innate immunity |
J:110094
|
abnormal macrophage physiology |
J:110094
|
normal
immune system phenotype |
J:110094
|
Myd88m3Btlr/Myd88m3Btlr
C57BL/6J-Myd88m3Btlr
|
normal
immune system phenotype |
J:156848
|
Myd88M4Btlr/Myd88+
C57BL/6J-Myd88M4Btlr
|
decreased tumor necrosis factor secretion |
J:254917
|
Myd88M4Btlr/Myd88M4Btlr
C57BL/6J-Myd88M4Btlr
|
decreased tumor necrosis factor secretion |
J:254917
|
Myd88poc/Myd88+
C57BL/6-Myd88poc
|
normal
immune system phenotype |
J:110094
|
Myd88poc/Myd88poc
C57BL/6-Myd88poc
|
abnormal immune system physiology |
J:110094
|
abnormal macrophage physiology |
J:110094
|
normal
immune system phenotype |
J:110094
|
increased susceptibility to bacterial infection |
J:110094
|
increased susceptibility to Herpesvirales infection |
J:110094
|
Myd88tm1.1Defr/Myd88tm1.1Defr
B6.129P2(SJL)-Myd88tm1.1Defr
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:224849
|
abnormal macrophage physiology |
J:224849
|
abnormal microglial cell physiology |
J:224849
|
decreased effector memory CD4-positive, alpha-beta T cell number |
J:224849
|
decreased interferon-gamma secretion |
J:224849
|
decreased leukocyte cell number |
J:224849
|
decreased macrophage cell number |
J:224849
|
decreased monocyte cell number |
J:224849
|
decreased neutrophil cell number |
J:224849
|
demyelination |
J:224849
|
increased susceptibility to Coronaviridae infection |
J:224849
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality |
J:224849
|
paralysis |
J:224849
|
Myd88tm1.1Medz/Myd88tm1.1Medz Foxp3tm4(YFP/icre)Ayr/Foxp3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
|
normal
immune system phenotype |
J:209373
|
Myd88tm1.1Medz/Myd88tm1.1Medz Tg(Cd4-cre)1Cwi/0
involves: C57BL/6 * DBA/2
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:209373
|
abnormal memory T cell physiology |
J:209373
|
abnormal T-helper 1 physiology |
J:209373
|
abnormal T-helper 17 cell physiology |
J:209373
|
Myd88tm1.1Papr/Myd88tm1.1Papr
Not Specified
|
normal
reproductive system phenotype |
J:178967
|
Myd88tm1a(EUCOMM)Wtsi/Myd88tm1a(EUCOMM)Wtsi
C57BL/6N-Myd88tm1a(EUCOMM)Wtsi/Wtsi
|
decreased mean corpuscular volume |
J:175295
|
increased body weight |
J:175295
|
Myd88tm1Aki/Myd88tm1Aki
B6.129-Myd88tm1Aki
|
abnormal susceptibility to bacterial infection |
J:189854
|
decreased interleukin-6 secretion |
J:189854
|
decreased tumor necrosis factor secretion |
J:189854
|
Myd88tm1Aki/Myd88tm1Aki
B6.129P2-Myd88tm1Aki
|
abnormal chemokine secretion |
J:102879
|
abnormal cytokine secretion |
J:116670,
J:162707
|
abnormal dendritic cell differentiation |
J:139001
|
abnormal dendritic cell physiology |
J:116670,
J:118954
|
abnormal enterocyte morphology |
J:128329
|
abnormal immune system physiology |
J:121070
|
abnormal innate immunity |
J:162707
|
abnormal macrophage physiology |
J:116670
|
abnormal nervous system physiology |
J:122826
|
abnormal neuron differentiation |
J:129957
|
abnormal NK cell physiology |
J:139001
|
abnormal response to infection |
J:121070
|
abnormal susceptibility to hearing loss |
J:123946
|
abnormal T cell physiology |
J:97662
|
bronchiolitis |
J:162707
|
decreased inflammatory response |
J:123946
|
decreased interferon-alpha secretion |
J:97662
|
decreased interferon-gamma secretion |
J:116763,
J:118954
|
decreased interleukin-6 secretion |
J:118954,
J:121070
|
decreased interleukin-12 secretion |
J:116670
|
decreased interleukin-12b secretion |
J:116763,
J:118954
|
decreased susceptibility to kidney reperfusion injury |
J:146120
|
decreased susceptibility to parasitic infection |
J:116763
|
decreased tumor necrosis factor secretion |
J:116670,
J:116763,
J:121070
|
increased apoptosis |
J:102879
|
increased dendritic cell number |
J:116763
|
increased physiological sensitivity to xenobiotic |
J:102879
|
increased susceptibility to Coronaviridae infection |
J:162707
|
increased susceptibility to Coronaviridae infection induced morbidity/mortality |
J:162707
|
increased susceptibility to Picornaviridae infection |
J:97662
|
rectal hemorrhage |
J:128329
|
Myd88tm1Aki/Myd88tm1Aki
C.129P2-Myd88tm1Aki
|
decreased susceptibility to induced arthritis |
J:178054
|
Myd88tm1Aki/Myd88tm1Aki
involves: 129P2/OlaHsd
|
abnormal airway responsiveness |
J:147534
|
abnormal cytokine level |
J:174941
|
abnormal cytokine secretion |
J:167340
|
abnormal dendritic cell physiology |
J:137522,
J:174941
|
abnormal enterocyte physiology |
J:167340
|
abnormal glucose homeostasis |
J:124334
|
abnormal gut flora balance |
J:177506
|
abnormal interferon level |
J:137522
|
abnormal macrophage physiology |
J:174941
|
abnormal neutrophil physiology |
J:145345
|
abnormal pancreatic beta cell morphology |
J:148283
|
abnormal pancreatic beta cell physiology |
J:148283
|
abnormal respiratory system physiology |
J:147534
|
abnormal retina progenitor cell morphology |
J:141070
|
abnormal tumor necrosis factor level |
J:103464,
J:124334
|
decreased circulating tumor necrosis factor level |
J:139030
|
decreased interferon-alpha secretion |
J:144400
|
decreased interferon-gamma secretion |
J:210086
|
decreased interleukin-6 secretion |
J:167340
|
decreased liver tumor incidence |
J:103464
|
decreased pancreatic beta cell mass |
J:148283
|
decreased susceptibility to experimental autoimmune encephalomyelitis |
J:105435
|
normal
digestive/alimentary phenotype |
J:177506
|
normal
hematopoietic system phenotype |
J:135830
|
hyperglycemia |
J:148283
|
increased IgA level |
J:210086
|
increased IgE level |
J:115059
|
increased IgG1 level |
J:115059
|
increased susceptibility to bacterial infection |
J:210086
|
increased susceptibility to induced colitis |
J:167340
|
increased susceptibility to Picornaviridae infection |
J:137522
|
small pancreatic islets |
J:148283
|
Myd88tm1Aki/Myd88tm1Aki
involves: 129P2/OlaHsd * C57BL/6
|
abnormal chemokine secretion |
J:141143
|
abnormal cytokine secretion |
J:117688
|
abnormal dendritic cell physiology |
J:122394
|
abnormal macrophage physiology |
J:117688,
J:141143
|
decreased IgG2b level |
J:137066
|
decreased IgG3 level |
J:137066
|
decreased IgG level |
J:137066
|
decreased incidence of tumors by chemical induction |
J:162097
|
decreased interleukin-1 beta secretion |
J:124226
|
decreased interleukin-6 secretion |
J:147023
|
normal
immune system phenotype |
J:132662
|
Myd88tm1Aki/Myd88tm1Aki
Not Specified
|
abnormal cytokine secretion |
J:88906,
J:89257
|
abnormal dendritic cell physiology |
J:96773
|
abnormal macrophage physiology |
J:96773
|
abnormal NK cell physiology |
J:88906
|
abnormal NK T cell physiology |
J:88906
|
abnormal T cell physiology |
J:96773
|
decreased B cell proliferation |
J:96773
|
increased susceptibility to Herpesvirales infection |
J:88906
|
Myd88tm1Aki/Myd88tm1Aki Tg(Vil-Myd88)#Lvh/0
involves: 129P2/OlaHsd
|
normal
digestive/alimentary phenotype |
J:177506
|
Myd88tm1Defr/Myd88tm1Defr Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal NK cell physiology |
J:139001
|
Myd88tm1Defr/Myd88tm1Defr Tg(Itgax-cre)1-1Reiz/0
B6.Cg-Myd88tm1Defr Tg(Itgax-cre)1-1Reiz
|
abnormal dendritic cell antigen presentation |
J:139001
|
abnormal dendritic cell differentiation |
J:139001
|
abnormal dendritic cell physiology |
J:139001
|
abnormal NK cell physiology |
J:139001
|
abnormal T-helper 1 cell differentiation |
J:139001
|
decreased circulating interleukin-6 level |
J:139001
|
decreased circulating interleukin-12b level |
J:139001
|
decreased IgG1 level |
J:139001
|
decreased IgG2b level |
J:139001
|
decreased IgG2c level |
J:139001
|
Myd88tm1Defr/Myd88tm1Defr Tg(Vil1-cre)997Gum/0
involves: 129P2/OlaHsd * C57BL/6J * SJL
|
abnormal gut flora balance |
J:177506
|
Myd88tm1Hlz/Myd88tm1Hlz
B6.129P2-Myd88tm1Hlz
|
abnormal chemokine level |
J:188968
|
decreased circulating alanine transaminase level |
J:188968
|
decreased circulating aspartate transaminase level |
J:188968
|
decreased circulating interleukin-6 level |
J:188968
|
decreased circulating interleukin-10 level |
J:188968
|
decreased circulating interleukin-12b level |
J:188968
|
decreased interleukin-6 secretion |
J:188968
|
decreased interleukin-10 secretion |
J:188968
|
decreased neutrophil cell number |
J:188968
|
decreased tumor necrosis factor secretion |
J:188968
|
Myd88tm1Hlz/Myd88tm1Hlz Lyz2tm1(cre)Ifo/Lyz2+
B6.129P2-Myd88tm1Hlz Lyz2tm1(cre)Ifo
|
abnormal circulating chemokine level |
J:188968
|
decreased CXCL10 level |
J:188968
|
normal
immune system phenotype |
J:188968
|
increased circulating alanine transaminase level |
J:188968
|
increased circulating aspartate transaminase level |
J:188968
|
increased circulating tumor necrosis factor level |
J:188968
|
increased susceptibility to injury |
J:188968
|
Myd88tm1Jcbr/Myd88tm1Jcbr Tg(Nes-cre)1Kln/0
B6.Cg-Myd88tm1Jcbr Tg(Nes-cre)1Kln
|
abnormal glucose homeostasis |
J:153664
|
abnormal parametrial fat pad morphology |
J:153664
|
decreased body length |
J:153664
|
decreased circulating insulin level |
J:153664
|
decreased epididymal fat pad weight |
J:153664
|
decreased fat cell size |
J:153664
|
decreased food intake |
J:153664
|
decreased locomotor activity |
J:153664
|
decreased susceptibility to diet-induced obesity |
J:153664
|
decreased total body fat amount |
J:153664
|
increased energy expenditure |
J:153664
|
increased insulin sensitivity |
J:153664
|